Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control [1]

C. L. Harper-Wynne, K. Sumpter, C. Ryan, K. Priest, A. Norton, P. Ross, H. E.R. Ford, P. Johnson, M. E.R. O'Brien

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control [1]'. Together they form a unique fingerprint.